Carmenta Bio

Palo Alto, United States Founded: 2012 • Age: 14 yrs Acquired By Progenity
Diagnostics for womens health
Annual revenue - Latest available
Total funding $2.6M 2 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About Carmenta Bio

Carmenta Bio is a company based in Palo Alto (United States) founded in 2012 was acquired by Progenity in April 2015. Carmenta Bio has raised $2.59 million across 2 funding rounds from investors including Progenity. Carmenta Bio operates in a competitive market with competitors including Celmatix, Metabolomic Diagnostics, adyn, LIA Diagnostics and Confer Health, among others.

  • Headquarter Palo Alto, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Carmenta Bioscience Inc
Operational Areas
Healthcare → Health Technology & Digital Health Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $2.59 M (USD)

    in 2 rounds

  • Latest Funding Round
    $2 M (USD), Seed

    Aug 07, 2013

  • Investors
  • Employee Count
    Not available
  • Acquired by
    Progenity

    (Apr 29, 2015)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Carmenta Bio

Carmenta Bio has successfully raised a total of $2.59M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2 million completed in August 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Carmenta Bio

Carmenta Bio has secured backing from 1 investor. Prominent investors backing the company include Progenity.

All
Investor Description Founded Year Domain Location
Non-invasive prenatal genomic testing is provided for genetic disorders.
Locked Locked Locked
Premium access

Investor details for Carmenta Bio

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Carmenta Bio

Investments
Premium access

Investment portfolio details for Carmenta Bio

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Carmenta Bio

Premium access

Detailed financials for Carmenta Bio

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Carmenta Bio Comparisons

Carmenta Bio Primary company
Description
Diagnostics for women's health
Location
Palo Alto, United States
Founded Year
2012
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Carmenta Bio

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Carmenta Bio

Carmenta Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celmatix, Metabolomic Diagnostics, adyn, LIA Diagnostics and Confer Health, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Fertility decisions are optimized using data analytics and genomics.
Locked Locked Locked
Diagnostics and prognostics for maternal health are developed using metabolomics.
Locked Locked Locked
Provider of DNA and hormone analysis based birth control optimization kits
Locked Locked Locked
Disposable paper pregnancy test kits
Locked Locked Locked
Clinical-grade diagnostic tests for home use are developed.
Locked Locked Locked
Exosome-based diagnostic products for health screening are offered.
Premium access

Detailed competitors of Carmenta Bio

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Carmenta Bio

Premium access

Complete news archive for Carmenta Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Carmenta Bio

Carmenta Bio was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Carmenta Bio is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.

Carmenta Bio is a funded company, having raised a total of $2.59M across 2 funding rounds to date.

Carmenta Bio was founded in 2012 in Palo Alto, United States, as a Stanford spin-out focused on biotechnology for womens health. Proprietary computational algorithms were combined with protein sera measurements in its platform to enable maternal diagnostics. A diagnostic test for preeclampsia was offered for both symptomatic and asymptomatic expectant mothers. The company was acquired by Progenity in April 2015.

Carmenta Bio's top competitors include Celmatix, Metabolomic Diagnostics and LIA Diagnostics.

Carmenta Bio has 1 investor. Key investors include Progenity.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available